Please login to the form below

Not currently logged in
Email:
Password:

renal disorders

This page shows the latest renal disorders news and features for those working in and with pharma, biotech and healthcare.

Boehringer signs renal disease research collaboration

Boehringer signs renal disease research collaboration

Boehringer Ingelheim has signed a new research collaboration with Hydra Biosciences that will this time focus on renal diseases and disorders. ... developing strong research partners to discover new treatments for renal disease and related disorders.

Latest news

  • AZ pays $273m for Ardelyx renal disease drug AZ pays $273m for Ardelyx renal disease drug

    AZ pays $273m for Ardelyx renal disease drug. Phase II candidate could tackle fluid overload in kidney and heart disorders. ... accumulation. Ardelyx hopes the drug will be able to tackle fluid overload in kidney and heart disorders such as end-stage

  • Disease area focus: Hepatitis C

    While it has always been regarded as a liver disease, it has also been associated with numerous haematological, renal, dermatological, rheumatic, autoimmune and brain disorders.

  • Mochida and Wyeth in novel vanilloid pain tie-up

    Existing painkillers sometimes cause gastrointestinal disorders or renal disorders, which limits their use.

  • Amgen to buy kidney drug firm Ilypsa for USD 420m

    Ilypsa's focus on renal disorders complements Amgen's existing drug portfolio, which includes Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) artificial versions of human erythropoietin used to treat anaemia in

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics